Nexplanon and Blood Pressure in Hypertensive Patients
Nexplanon (etonogestrel implant) can be used in women with controlled hypertension (BP <160/100 mmHg) with close monitoring, but women with a history of hypertension-related diseases should be discouraged from using hormonal contraception. 1
Key Distinction: Progestin-Only vs. Combined Hormonal Contraceptives
The critical point is that Nexplanon is a progestin-only contraceptive, which has a fundamentally different blood pressure profile compared to combined estrogen-progestin contraceptives:
Combined Hormonal Contraceptives (NOT Nexplanon):
- Cause a minor but consistent increase in blood pressure (5-7 mmHg) 2
- Frank hypertension develops in 0.6-2.8% of users 2
- The mechanism involves ethinyl estradiol increasing hepatic angiotensinogen synthesis and stimulating the renin-angiotensin-aldosterone system 2
- Contraindicated in women with controlled hypertension or BP <160/100 mmHg 2
- Formally contraindicated in uncontrolled hypertension (≥160/100 mmHg) 2
Progestin-Only Methods (Including Nexplanon):
- No restrictions on use in women with controlled hypertension or BP <160/100 mmHg 2
- The advantages outweigh theoretical or proven risks even in women with uncontrolled hypertension (≥160/100 mmHg) or history of cardiovascular disease 2
- Progestin-only methods are the hormonal alternative of choice for hypertensive women 2
- Data on blood pressure effects are reassuring, though from smaller studies 2
FDA Labeling Guidance for Nexplanon
The FDA label provides specific guidance 1:
- Women with hypertension-related diseases or renal disease should be discouraged from using hormonal contraception
- For well-controlled hypertension, Nexplanon use can be considered
- Close monitoring is mandatory for hypertensive women using Nexplanon
- Remove Nexplanon if:
- Sustained hypertension develops during use
- Significant BP increase does not respond adequately to antihypertensive therapy
- Annual blood pressure checks are required for all Nexplanon users
Clinical Evidence on Blood Pressure Effects
Research studies show mixed but generally reassuring findings:
- One Nigerian study found statistically significant increases in systolic BP at 1 year, but no clinically detectable abnormalities 3
- Another study showed significant reductions in both systolic and diastolic BP at 12 months (though within normal range) 4
- A 2019 review confirmed that progestin-only contraception appears safe regarding hypertension risk 5
- A 2026 analysis noted that progestin-only pills and implants have lower or more neutral blood pressure signals compared to combined hormonal contraceptives 6
Practical Management Algorithm
For patients with controlled hypertension (BP <160/100 mmHg):
- Nexplanon can be considered as a contraceptive option
- Ensure BP is well-controlled on current antihypertensive regimen
- Measure baseline BP before insertion
- Monitor BP at 3-6 months post-insertion
- Continue annual BP monitoring
- Remove if sustained hypertension develops or BP becomes unresponsive to therapy
For patients with uncontrolled hypertension (BP ≥160/100 mmHg):
- Optimize BP control first
- Nexplanon remains an option (advantages outweigh risks per guidelines) 2
- Requires more intensive monitoring
- Consider alternative non-hormonal methods if BP cannot be controlled
For patients with hypertension-related complications:
- Renal disease: discouraged per FDA label 1
- History of cardiovascular disease: advantages still outweigh risks per guidelines 2
Important Caveats
- The evidence base for progestin-only methods and blood pressure comes from smaller studies compared to combined hormonal contraceptives 2
- Individual patient response varies—some may experience BP increases while others may see decreases 3, 4
- Blood pressure measurement before prescribing any hormonal contraception is the only clinical examination recommended by WHO 2
- The cumulative cardiovascular risk from even small BP elevations over time is clinically significant, particularly in reproductive-aged women 7
Bottom line: Nexplanon is significantly safer than combined hormonal contraceptives for hypertensive patients and can be used with appropriate monitoring, but requires individualized risk assessment and close BP surveillance.